In this perspective, we confirm the importance of a longitudinal assessment of the serological response to COVID-19 vaccination over time, encompassing the assessment of both anti-SARS-CoV-2 IgA and IgG neutralizing antibodies, since these measurements may help to the timely identification of vaccine recipients at major risk of immediate infection due to a blunted response, as well as those at enhanced likelihood of developing breakthrough infections on follow-up due to a faster decline in immunity [41]. Here, CD79A is linked to COVID-19.